News Pfizer builds on Braftovi bowel cancer OK with survival data Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.
News Novartis bags FDA okay for BRAF-positive tumour combination Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in t
News NHS cleared to use Novo Nordisk's long-acting growth hormone Novo Nordisk's long-acting injectable Sogroya has been backed for NHS use in young people with growth hormone deficiency.